Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

CXCR4-SERINE339 regulates cellular adhesion, retention and mobilization, and is a marker for poor prognosis in acute myeloid leukemia.

Brault L, Rovó A, Decker S, Dierks C, Tzankov A, Schwaller J.

Leukemia. 2014 Mar;28(3):566-76. doi: 10.1038/leu.2013.201. Epub 2013 Jul 2.

PMID:
23817178
2.

CXCR4 regulates migration and development of human acute myelogenous leukemia stem cells in transplanted NOD/SCID mice.

Tavor S, Petit I, Porozov S, Avigdor A, Dar A, Leider-Trejo L, Shemtov N, Deutsch V, Naparstek E, Nagler A, Lapidot T.

Cancer Res. 2004 Apr 15;64(8):2817-24.

3.

Role of CXCR4 in the pathogenesis of acute myeloid leukemia.

Peled A, Tavor S.

Theranostics. 2013;3(1):34-9. doi: 10.7150/thno.5150. Epub 2013 Jan 13. Review.

4.

Functional CXCR4-expressing microparticles and SDF-1 correlate with circulating acute myelogenous leukemia cells.

Kalinkovich A, Tavor S, Avigdor A, Kahn J, Brill A, Petit I, Goichberg P, Tesio M, Netzer N, Naparstek E, Hardan I, Nagler A, Resnick I, Tsimanis A, Lapidot T.

Cancer Res. 2006 Nov 15;66(22):11013-20.

5.

Dissection of PIM serine/threonine kinases in FLT3-ITD-induced leukemogenesis reveals PIM1 as regulator of CXCL12-CXCR4-mediated homing and migration.

Grundler R, Brault L, Gasser C, Bullock AN, Dechow T, Woetzel S, Pogacic V, Villa A, Ehret S, Berridge G, Spoo A, Dierks C, Biondi A, Knapp S, Duyster J, Schwaller J.

J Exp Med. 2009 Aug 31;206(9):1957-70. doi: 10.1084/jem.20082074. Epub 2009 Aug 17.

6.

A CXCR4 antagonist leads to tumor suppression by activation of immune cells in a leukemia-induced microenvironment.

Han AR, Lee JY, Kim HJ, Min WS, Park G, Kim SH.

Oncol Rep. 2015 Dec;34(6):2880-8. doi: 10.3892/or.2015.4297. Epub 2015 Sep 21.

PMID:
26398122
7.

The prognostic value of CXCR4 in acute myeloid leukemia.

Ahn JY, Seo K, Weinberg OK, Arber DA.

Appl Immunohistochem Mol Morphol. 2013 Jan;21(1):79-84. doi: 10.1097/PAI.0b013e3182606f4d.

PMID:
22914607
8.

CXCR4 downregulation of let-7a drives chemoresistance in acute myeloid leukemia.

Chen Y, Jacamo R, Konopleva M, Garzon R, Croce C, Andreeff M.

J Clin Invest. 2013 Jun;123(6):2395-407. doi: 10.1172/JCI66553. Epub 2013 May 8.

9.

Overexpression of CXCR4 predicts adverse overall and event-free survival in patients with unmutated FLT3 acute myeloid leukemia with normal karyotype.

Konoplev S, Rassidakis GZ, Estey E, Kantarjian H, Liakou CI, Huang X, Xiao L, Andreeff M, Konopleva M, Medeiros LJ.

Cancer. 2007 Mar 15;109(6):1152-6.

10.

CXCR4 inhibitors selectively eliminate CXCR4-expressing human acute myeloid leukemia cells in NOG mouse model.

Zhang Y, Patel S, Abdelouahab H, Wittner M, Willekens C, Shen S, Betems A, Joulin V, Opolon P, Bawa O, Pasquier F, Ito M, Fujii N, Gonin P, Solary E, Vainchenker W, Coppo P, De Botton S, Louache F.

Cell Death Dis. 2012 Oct 4;3:e396. doi: 10.1038/cddis.2012.137.

11.

Pan-histone deacetylase inhibitor panobinostat depletes CXCR4 levels and signaling and exerts synergistic antimyeloid activity in combination with CXCR4 antagonists.

Mandawat A, Fiskus W, Buckley KM, Robbins K, Rao R, Balusu R, Navenot JM, Wang ZX, Ustun C, Chong DG, Atadja P, Fujii N, Peiper SC, Bhalla K.

Blood. 2010 Dec 9;116(24):5306-15. doi: 10.1182/blood-2010-05-284414. Epub 2010 Sep 1.

12.

CXCR4 is a prognostic marker in acute myelogenous leukemia.

Spoo AC, Lübbert M, Wierda WG, Burger JA.

Blood. 2007 Jan 15;109(2):786-91. Epub 2006 Aug 3.

13.

Prognostic value of CXCR4 and FAK expression in acute myelogenous leukemia.

Tavernier-Tardy E, Cornillon J, Campos L, Flandrin P, Duval A, Nadal N, Guyotat D.

Leuk Res. 2009 Jun;33(6):764-8. doi: 10.1016/j.leukres.2008.10.014. Epub 2008 Nov 29.

PMID:
19042019
14.

VLA-4 and CXCR4 expression levels show contrasting prognostic impact (favorable and unfavorable, respectively) in acute myeloid leukemia.

Bae MH, Oh SH, Park CJ, Lee BR, Kim YJ, Cho YU, Jang S, Lee JH, Kim N, Park SH, Lim JH, Seo EJ, Lee KH.

Ann Hematol. 2015 Oct;94(10):1631-8. doi: 10.1007/s00277-015-2442-8. Epub 2015 Jul 10.

PMID:
26155911
15.

Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100.

Nervi B, Ramirez P, Rettig MP, Uy GL, Holt MS, Ritchey JK, Prior JL, Piwnica-Worms D, Bridger G, Ley TJ, DiPersio JF.

Blood. 2009 Jun 11;113(24):6206-14. doi: 10.1182/blood-2008-06-162123. Epub 2008 Dec 2.

16.

The CXCR4 antagonist AMD3100 impairs survival of human AML cells and induces their differentiation.

Tavor S, Eisenbach M, Jacob-Hirsch J, Golan T, Petit I, Benzion K, Kay S, Baron S, Amariglio N, Deutsch V, Naparstek E, Rechavi G.

Leukemia. 2008 Dec;22(12):2151-5158. doi: 10.1038/leu.2008.238. Epub 2008 Sep 4.

PMID:
18769446
17.

Migratory behavior of leukemic cells from acute myeloid leukemia patients.

Voermans C, van Heese WP, de Jong I, Gerritsen WR, van Der Schoot CE.

Leukemia. 2002 Apr;16(4):650-7.

18.

Curcumin reduces expression of Bcl-2, leading to apoptosis in daunorubicin-insensitive CD34+ acute myeloid leukemia cell lines and primary sorted CD34+ acute myeloid leukemia cells.

Rao J, Xu DR, Zheng FM, Long ZJ, Huang SS, Wu X, Zhou WH, Huang RW, Liu Q.

J Transl Med. 2011 May 19;9:71. doi: 10.1186/1479-5876-9-71.

19.

Relation between CXCR-4 expression, Flt3 mutations, and unfavorable prognosis of adult acute myeloid leukemia.

Rombouts EJ, Pavic B, Löwenberg B, Ploemacher RE.

Blood. 2004 Jul 15;104(2):550-7. Epub 2004 Mar 30.

20.

Inhibition of CXCR4 with the novel RCP168 peptide overcomes stroma-mediated chemoresistance in chronic and acute leukemias.

Zeng Z, Samudio IJ, Munsell M, An J, Huang Z, Estey E, Andreeff M, Konopleva M.

Mol Cancer Ther. 2006 Dec;5(12):3113-21.

Items per page

Supplemental Content

Write to the Help Desk